

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: **PCT/EP01/06976**

(22) International Filing Date: **20 June 2001 (20.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. Nature 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., Science 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., Science 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., Proc. Natl. Acad. Sci. USA 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., Nature 376, 70-74, 1995; Rodewald & Sato, Oncogene 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., Nature 376, 70-74, 1995; Dumont et al., Genes Dev. 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., Science 277, 55-60, 1997; Suri et al., cell 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., Science 282, 468-471, 1998; Thurston et al., Science 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., Science 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in
5 mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of
10 endothelial-periendotherial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated
15 expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies
20 (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60,
25 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al.,
30 Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).
- Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


30

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
molecules of general formula I

15



20

in which

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

25

R₃ und R₄


a) each independently from each other have the meaning
of lower alkyl,

b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogene, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherificated or
esterificated hydroxy, nitro, cyano, carboxy, esterificated
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one ore more N-atoms carry
an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranyl acid derivatives of general formula IV

30



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$, $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the group


10



15

or A, Z and R^1 together form the group

20



m, n and o

q

 $R_a, R_b, R_c, R_d, R_e, R_f$

5

X

Y

p

 R^1

10

15

 R^2

20

 R^3

25

 R^4, R^5, R^6 and R^7

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=NR^{10}$, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,

has the meaning of group $=NR^9$ or $=N-$,has the meaning of group $-(CH_2)_p$,

has the meaning of integer 1-4,


has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C_{1-6} -alkoxy, C_{1-6} -alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.


More preferentially compounds of general formula V




V,

- 15 in which
R¹ has the meaning of group


20




14



in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$

in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts can be used as compound I or II in the inventive pharmaceutical
composition.

These compounds have the same properties as already mentioned above under
compound IV and can be used for the treatment of angiogeneous diseases.
Compositions comprise compounds of general formulars I, IV and V, alone or in
combination.

The above mentioned compounds are also claimed matter within the inventive
combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences
coding for such peptides, which are used for the treatment of angiogeneous
diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59
of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of
main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector
15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are descibed in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods
15 descibed by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor
20 growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in E. coli as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of a specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 25 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 30 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.


20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as
25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as
30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

20 X has the meaning of imino, oxa or thia;


Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, 25 carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, 30 phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV

5



in which

10

A

has the meaning of group $=NR^2$,


W

has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$,
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7


substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V





V,

in which


R^1 has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$


in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

15

16. Pharmaceutical compositions according to claim 15 which comprise as
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

20

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15 <140>
<141>

<160> 59

20 <210> 1
<211> 1835
<212> DNA
<213> Human

25 <400> 1

```

      ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
      agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
      tttctttttt tttttttaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
      actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
      tatacaaaca gccaaaaaac cataatggtg ccacagggat ggagcagggg agggcatctc 300
      taacgtgtcc tctagtctat cttcgctaaa cagaaccacac gttacacatg ataactagag 360
      agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
      aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaagggggt 480
      aagaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
      tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
      attaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaaggga gacgctgaga 660
      tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
      catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacca agcaaaatct 780
      aagcaaaatc agacaacgaa gcagcgtatc atagctttcc tttgagagaa cgcatacctt 840
      gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtgata 900
      aaaatgactc aagcgtatga aaaagtttca tctgttccca gaatccgagg gagaactgag 960
      gtgatecgtta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
      gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggagaca 1080
      tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
      gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
      ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260
      tcaggtgggt ctgcgatagc tcatttaatg ttaaacgcca tcaggggcct ctcctcccgt 1320
      ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
      gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggtcgtc tcctcctgca 1440
      ggctgggcag ctggccacca cttctccgac tcgacccctc caacaagcat cgcagggcac 1500
      tgtcctcggg ggtacagacc gtggtcccac attcgttacc actctgttcc acgtcatcca 1560
      ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctcttcc tgctggtgct 1620
      cttggacggg cgggtagtgc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
      attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
      cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
      gagacgaacc acgcccgggg gtgcggaagc ggcct

```

60 <210> 2
<211> 581
<212> DNA
<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
acactaaca cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa tgtaggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

<400> 3

25 tagagatgtt ggttgatgac ccccgggac tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcac tacatcacag aggacatgct catgtcgcg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tcctgcgcat tgcaggtctg tgtcaggaca ctgctcagag ttacacctt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420
tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
30 atgaagtcc agagtttgtt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
35 <213> Human

<400> 4

40 cccacaacac agggggccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggc tgagaagggt ccctgggtcg 180
ggggtgctgc ttggccttgc cgtgccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggtta agcaccagg agatgagtcc aaccaccaac atgaagatga 300
tgaagatggt cttctccgtg gggcgagaga caaagcagtc cacgaggtag gggcaggggtg 360
45 ctcgctggca cacaacacg ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgaga gcacactggc gacatagggt cccatcagt 480
ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgctcta 540
cgcccgccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agtccccct 600
ccttctgccg cagccgctct tctcgccgag acaggtaa atgacatggccc aggtagacca 660
50 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
aggcctgggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
agagcaccgt cagccagatc ttaccacca cggctcgagt ctctggacc tgggtccagca 900
acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
55 gcacgtcagt gtgtcagcat ggcctcctt tegtgcgcc agcaacaagc ctgcaggag 1020
gtctgccacg ccggttctac cgcctgcctg ccgggcggcc cagggtggag tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5
60 <211> 1015
<212> DNA
<213> Human

<400> 5

65 gaggataggg agcctggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
agtggggagc ataatagcaa acaccccctt gggtcgcaca tgtacaggaa tgggacccag 180
ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaagtg gggccagggc 240
ccagacccaa gaggagaggg tgggtccgcag acaccccggg atgtcagcat cccccgacct 300
5 gccttctggc ggcacctccc ggggtgctgtg ttgagtcagc aggcattggg tgagagcctg 360
gtatatgctg ggaacagggg gcaggggcca agcggttcct cttcagcctt gacttgggccc 420
atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgggtg caggacaggt 480
gtcccttcag tcctctgggt atgacctcaa gtcctacttg ggcctgcag cccagcctgt 540
gttgtaacct ctgcttcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
10 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720
ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780
gagcctagag caggaggtcc cgaacttctg cattcacaga ccacctccac aattgttata 840
accaaaggcc tcctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
15 cttctgactt tagcctcgtg ctgagccgtg tatecatgca gtcattgttca cgtgctagtt 960
acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

<210> 6
<211> 2313
20 <212> DNA
<213> Human

<400> 6

25 ccagagcagg cctggtggtg agcagggacg gtgcaccgga cggcgggatc gagcaaatgg 60
gtctggccat ggagcacgga gggctctacg ctcgggcggg gggcagctct cggggctgct 120
ggtattacct gcgctacttc ttctctctcg tctccctcat ccaattcttc atcatcctgg 180
ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240
30 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
ccaacttgac caaggagctc aacttcacca cccgcgcaa ggatgccatc atgcagatgt 360
ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcatgctga 540
atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
35 ataaggaaag cgtgctgctg aacaaacgcg tggcgaggga acagctgggt gaatgctga 660
aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720
agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
ctcgggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
40 ggtggaggag ctggcccggg gcctccgggc ggatatcgaa cgcgtggccc gcgagaactc 960
agacctcaa cgccagaagc tggaagccca gcagggcctg cgggccagtc aggaggcgaa 1020
acagaagggt gagaaggagg ctgagggccc ggaggccaag ctccaagctg aatgctcccg 1080
gcagaccag ctgagcgtgg aggagaaggc ggtgctgcgg aaggaacgag acaacctggc 1140
caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200
45 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260
gcccattggc cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttaa 1320
gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcggcggtt tgcggaggat 1440
gcagggatat gctcacagcg cccgacacaa cccctcccg cgcgcccaa ccacccaggg 1500
50 ccacccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgcg 1560
cctcacgac cctcaccag agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620
ctgacgtcac atatcacgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
acgtcacacc gagatgcagc aacgacgtca cgggccatgt cgacgtcaca catattaatg 1800
55 tcacacagac gcggcgatgg catcacacag acggtgatga tgtcacacac agacacagtg 1860
acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920
ccctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgacctggc 1980
acacgggcca aggtacccac aggatcccat cccctcccg acagccctgg gcccagcac 2040
ctcccctcct ccagcttctt ggcctcccag ccacttctc acccccagt cctggaccgg 2100
60 gaggtgagaa caggaagcca ttcacctcg ctcttgagc gtgagtgtt ccaggacccc 2160
ctcggggccc tgagccgggg gtgaggggtc cctgttgtcg ggaggggagc cactccttct 2220
ccccaacte ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280
agtaaatacct taaaaaaaaa aaaaaaaaaa aaa

65 <210> 7
<211> 389

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

15 <210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagcccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggtg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggtt acaaatctgt gtgttatttc ttttctacct 180
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
40 ttttctttta aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccaat ttctaggaaa a

45 <210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttgct gatggcataa tccgggtgca acccaaactt 240
gagctcaagc caggtgagct taagccactg agcaagggaag atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtga cctaccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgtctgaca acccatgttc ttgcagccag tctcactgtt gtacacgat gtcagccatg 540
gggtgtcatgt cctctttttt gccttggtta tgggtgttacc ttccagccaa ggggtgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc ccccttagga actttgaaaa accaacatag 720
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780
atgcaaccaa ctaaactagt ataactcttg cactgttaat agaaagtgg gatagctttt 840
gctgttttgc gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctgagctaat ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaag tttttgtttg tgaatagtac ttgcaaaact 1020

5 tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatataa taatatTTTgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
 cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200
 ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
 5 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaataTTTta 1380
 ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440
 gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa

10 <210> 11
 <211> 389
 <212> DNA
 <213> Human

15 <400> 11

20 gggcaggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
 tcgtgccagc tctctcattt tttatgatga tgaccatcca cgggtgagaca agtgcccgac 120
 aggatgggtg gccagctga agcacaggcc gctctgcact tgcagataag acagccgtga 180
 ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
 cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
 cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
 acctcggccg cgaccacgct gggtagcga

25 <210> 12
 <211> 981
 <212> DNA
 <213> Human

30 <400> 12

35 tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
 tgccatgaga ctccatcagg cagtctataa agaccactgg gaggtgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcatgct tgcttggtgt ggtcattaaa aaccctagtt 240
 taggataaca acatattaat cagggcaaaa tacaatatgt tgatgcttgt tagtagagta 300
 acctcagaat caaaatggaa cgggttttaca gtgatatcat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
 40 taggataaca ggtctgcctg tttgaagatg aaaaataata cccattttaa atttgcccta 480
 ctcaatttcc ttctcagtca cattttaact tttaaacagc taatcactcc catctacaga 540
 ttaaggtgta tatgccacca aaaccttttg ccacctttaa aatttccttc aaagttttaa 600
 ctaatgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
 cacacagtggt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
 45 taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
 agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
 agtagctatt ctcatccttc cttggggaca caactgtcca taaggtgcta tccagagcca 900
 cactgcatct gcaccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
 ataagagtgc ttttgatgac g

50 <210> 13
 <211> 401
 <212> DNA
 <213> Human

55 <400> 13

60 ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
 tctctccccc agagcgaccc cccgggcagg tcggggccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggatcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
 acttcagcat atttagttgt cattaaaatt aagctgatat t

65 <210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacagggt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120
 10 tttgaaaatg ttaaatacaa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
 gaagtaaata tctggggccc atcgaccccc cactaagtag tttgtcacca tgttgtatct 300
 taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
 15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
 tactgaaaac aatggtgcca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
 attaatacag ctcaaagga gtagtaacca agcttttctg cccaggaagt acaaacatc 660
 actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720
 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
 20 acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840
 attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
 gcctatgttc tcagatatcc tgggttaggtc aggagtggga acccaaatc aattctttta 960
 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccgtgtc tggctctgaga tttttaaatg aggattacat taccctattt 60
 ataattattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
 aaacattatt agaaacaaac tgcctaatac cttataagac taaaaaaatc accaagatga 180
 35 aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgttagtggt tgtaagcac 240
 caatcttaac tatttcacct gcccgggcgg ccgctcgagg

<210> 16
 <211> 2041
 40 <212> DNA
 <213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60
 atagagggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
 atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
 aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
 50 atttaataat ggggttaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
 ttacctctag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420
 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
 caggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
 gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
 55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
 tagatatattg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720
 gcatttttga ctctctcagg atcaaaatac gagtctgcca actgtattaa atcctcctcc 780
 accccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
 60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
 tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
 atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
 ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
 ttgacatttc cttattttcc aaatcctggt caaaaactgc actgggacta tctctcccta 1200
 65 gtaaattgact ctgggaggat gctaattgcca gagcctcaga ctggtggtac atctgatatg 1260
 aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caatthttgtg caggaagctt 1380
 catcagtccc tgaaggcttt aatthtttttag caagggtctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaatthttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag cattttgcag agaggcacag ttttcacaat aatattggtt atcaccagta 1680
 agaattctctg gagcccaaaa aataatthtag taagtcagtt actgaagggtg tggtttcacc 1740
 tcccggtttc tgagggtacat ctttattaac aagaattctg ttagattcgt tagggacaga 1800
 agtgthttca gaacagtaaaa actcattagg aggactgcct atggthtttt cattcacaag 1860
 10 tgagtcacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcattha gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040
 t

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aagggttacag 180
 25 tgggccacga tcatgtcatt acactccagc ttgggtgaca aatgagact gtcta

<210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

<400> 18

35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggtga tcacattgtg caaatgggtg aagcattcaa acactttgaa 180
 accagattct agcagggttg aaaaacattaa gtcttggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtccttttg gttgcttttt attaatgagg agactattgt 300
 gatggcatat ctcttcacta tatttaatgc tttccaggga gtgttcattt tcatctttca 360
 40 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgtctgc tattcctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaagggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgcaaa acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtg gagctccatc 1020
 acaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtcccc aacagagact ctctttatag aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agccctgaca tggagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctggtt acaagtcttt 1440
 aatcatacag ctaaggaatt ccaaggcca catgcgagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 60 tgggtgtaaaa aagatgactg aaccttgagc ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcca 1680
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 tttgcagttc actgcaaactc ttttacatta aggcaaagat tgaaaacatg ctttaaccact 1980

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatatttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 aaaagctott gggtgcacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tctacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaatatt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460
 10 tttctagtga acaaaagggt cctattcttt tttaaaaaaa taaaataaaa cataaatatt 2520
 actcttccat attccttctg cctatattta gtaattaatt tattttatga taaagtctta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

25 ctccctaata gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

30 <210> 20
 <211> 2361
 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtgggacct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga ttagtggtat gtgcttgctg 240
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 40 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgccaaag cagcatctg gacagtgtg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggc aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagttgga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcgggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggatc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ctttcgatac atcggcaagc 840
 tgccttttga gcaggcagag agcaacatga agcgctacgg caagatcctc atgcaccaca 900
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgag cgatagggag gcccaggct gcagggccaa ctctgaggag ttcaccccca 1020
 tctttgcca taaccgcga gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggcc 1140
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggtcgctt ctgcgacgtc tttgacaagg ccctggctct gtgccagatg cacgacttcc 1260
 aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 60 tgggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcgg 1620
 accgagagga gaccaccctg atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800
 65 actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gccaggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggetgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaattgt cacagccctc acaagactaa agcggaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 ttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

<210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

30 tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaaag gtccaagcca ggctcaagaa 120
 ataaaaagg aggtttggag taatagataa gatgactcca atactcactc ttctaaggg 180
 caaaggtact ttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactct ttagaaggtg accattttgc actttaagg 360
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagctgga agagccttgg aagtttctat tacaatataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagt tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660
 ggcagggtc cctaattgtc attattacat ttccattccg aatgccagat gttaaaagt 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagtgag tgttttttcg 840
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

55 ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaatat gttattatag gcattttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 ttttttacta tatacatatg gaaaaaatca ttttctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420
 tcatttttgt tccggcggtt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540
 tggaggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt ttttctctca 660
 aaatgaatta cacaataaaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttatttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagt ctggtcaaag 840
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa caggtcttag 900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtatttgat 960
aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttggtttt 1020
tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
tgctatatca ctgctcagag gttaataatc ctactaact atcctatcaa atttgcaact 1140
ggcagtttac tctgatgatt caactccttt tctatctacc cccataatcc caccttactg 1200
atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
gcaccagccc ttctcactt tgccttgccc tcaaagctaa caccacttaa accacttaac 1320
tgcatctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440
10 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
ggtctgcaca aggtctgggt ctggctggct tcacttcctt tgcacactcg gaagcaggct 1560
gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
aacattcgcc ccactcttca atgacctatg ctgaaaaagt ggggatagca ttgaaagatt 1680
ccttcttctt ctttacgaag taggtgtatt taattttagg tccaagggca ttgccacag 1740
15 taagaacctg gatggtcaag ggtctttga gagggctaaa gctgcgaatt ctttccaatg 1800
ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
agctgccatt gttcctggat cccctctggg tccgctgttt cacttcgatg ttggtggctc 1980
cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
20 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttctttttgg 2100
agtctatgat gcgatcacia ccagctttta caca

<210> 24

<211> 1626

25 <212> DNA

<213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatatatt tgcttttaaaa tatatttttg 60
ttattttgaa tacagacatt ggctccaaat tttcatcttt gcacaatagt atgacttttc 120
actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gttaaggctg 180
tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
35 gaaaaaggca agacaaatgg cctcttgtag tgaatacttc ggcaaactta ttgggtcttc 360
atcttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
ggtagtgatg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atgggttttag 540
aaagctttgt ctaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaggggt 600
40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggta ctatctatga 660
atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
ccatttagcc cagtgggaaa gtcttggaac tcaggttacc cttgaaggat atgctggcag 780
ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
tctggaatgc attagttatg ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900
45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
atcctaacta actggctctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
aaacttagta gaggggattg tgtgtatatt atacaaattt aatacaatgt cttacattga 1080
taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
50 cgttggtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
atggattctt ctatagctaa atgagttccc tctggggaga gttctggtag tgcaatcaca 1320
atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380
tgtgtttgtt ttcactcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
tggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
55 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatattt 1560
tacttgaaaa tatttttaaa ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
aaaaaa

<210> 25

60 <211> 1420

<212> DNA

<213> Human

<400> 25

65

gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 10 tccttgtagt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcage catgctgata tattagaaat ggcatcccta tctacttact 480
 ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 tcagccttgc catgtatcag ttccacttga aatttgagac caattaaatt tcaactgttt 600
 15 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgcctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tgggttttgct 900
 20 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 25 tatagaaatt ttttatactg attggttcat agatggtcag tttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaaataaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

35 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcctta 180
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgtctc tgcaccattt atcacaccag gacagggctc ctcaacctgg gcgctactgt 300
 catttggggc caggtgattc ttctttgcaa gggctgtcct gtacctgccg gggcgggcgc 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctcc cactattcag 480
 40 gaggtggtcg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacacccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgtc cattggtggc accctgcttt gcctgtcctg ccaggacgag gcacctaca 120
 agccctaacc caggccccgc ccagggccac cagcaccact gcaaacaccg cacctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtagcagg tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcggga ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

60 <210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttcccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggg acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcate ttctctact cagttttcta 480
 ttatgcccg gctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540
 cttactcact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcctc 600
 aaagtctcat cggtatatct atgttaacct caagatggac tgagtctctg atggcagaac 660
 tattgctgtt ctctcccttt cttcatgccc tgttgaactc tcctaccage ttctcttctg 720
 attgactgaa ttgtgtgatg gcattgttgc ctccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatatat ttgaactttt 840
 taagttgcct ttagtttttg tcctgatttt tctttttaca attaccaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 20 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggccttcagt ccgtgtgggg 180
 30 cgcccgcgtg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggg acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaag acgtcatcaa tgaagggtgt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaaagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgaaggaagt 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agaggggtaca gcaggatga caagtacttc atggcctgag tatcgtactc 600
 ctccgttttc ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattctca atgccttctt cactttccac agtcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cacgggtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgctcttctt 840
 40 cttcttccag aaactgatgt cattttttaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaaag aaggtcagcg ccaggaaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaacccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gccccagtga gaccttgtcg taggacacgg tgaggggcag 1080
 ctccgttggtg gagcggttta tgaccatcag gtccttcacg cggttgctga gctggtcgat 1140
 45 gaacaggatg ggcaggtaat gcacggtttt ccccagctgg atcatcttca tgtaccgatg 1200
 cacatcggca ggcaggggag acccgtcaaa gacaaagttg tccgcctatca cgttcagcgc 1260
 cagccgcggt cgccagtggg aactggctc atccaggga ctcgtcggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccggg gagcagggtt atttcttctg gcttggggac 1380
 catgtaggtg gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga ttaggcata cagcgtccca ttgtttctcg ttttcttttg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggctg atgttgttct cagcaccag gtgggacctc gtcgtgggtg acacgctcag 1620
 ctgcagcttg ggccgcccg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcggggtgtag acgatgccgt acatgacca gcagggtgtg accacgtaga ccacgaacac 1740
 55 gccaccacc aagctgggtga aggagctgcg gcccc

<210> 30
 <211> 1546
 <212> DNA
 60 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgcta 60
 aaggccctgc caggctggga gggaaattgc cctgcctgct tctggagaaa gaagatattg 120

5 acaccatcta cgggcacccat ggaactgctt caagtgacca ttcttttttct tctgcccagt 180
 atttgacgca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggttact 240
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgttggtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccaatg aattacttaa aatgtctctg 360
 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aaccactgat 420
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaa 540
 acagaaatac caggtagtgt tctacaacca gatgcatcac cttctaaaac tgggtacatta 600
 10 acctcaatac cagttacaat tccagaaaac acctcacagt ctcaagtaat aggactgag 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccggtctt attccagtat tattttgccg 720
 gtgggttattg ctttgattgt aataacactt tcagtatttg ttctgggtggg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960
 15 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgaact tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080
 tccagctgac atgcaataat ttgatggaa caaaaagaac cccggggctc tctgttctc 1140
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200
 gaggagaatt tgtgagcagt gaatctgaca gccaggagg tgggctcgt gataggcatg 1260
 20 actttcctta atgttttaaag tttccgggc caagaatttt tatccatgaa gactttccta 1320
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380
 gcagggaaaa gttgcacgtg tattattaaa tattaggtag aaatcatacc atgctacttt 1440
 gtacatataa gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500
 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa

<210> 31
 <211> 750
 <212> DNA
 <213> Human

30

<400> 31

35 cacttgggca cccccatttt ctaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60
 aagggaagtg cctctgatgg cccaaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120
 atagcaaatg gatccttttt ggctccttt ggagcatgcc ttccctatct tatccttggc 180
 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300
 tgtacatgct tgctcattac aattttgaca ttttttacat agtgaagacc ccaaacatat 360
 40 cagtgaaca tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagttatac 480
 ttttaatagc ttccctcagca cactatttcc catgcattaa atatgataaa ataacttatc 540
 actgcccata ggtcttgtaa aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttggaact cctgacaggt 660
 45 ggattggaaa acggtgttta aagagaagag aacattttta cataaatgtc attaagaatc 720
 ccaaaggcct tatttgtcac caccgtcccc

<210> 32
 <211> 1620
 <212> DNA
 <213> Human

50

<400> 32

55 gcaattcccc cctcccacta aacgactccc agtaattatg ttacaacccc attggatgca 60
 gtgcagccat tcataagaac cttgggtgcc cagaaaaatc tgtccttttt ggtaccaaac 120
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180
 atctgtgcaa actctgatga tacctgcctt atgtggatct tttccacac tgccttcatt 240
 tttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300
 atgttctggg ttttttcctt ctttttagaa cccgcctcc atttaaaaaa ttaaaaaaaa 360
 60 aaaaaaaact ttttaacattt aaaaaataaa aattaacaaa atttcactta ttccaggaca 420
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acagteccct tctatccagc ttgccttcca tttatctcta 540
 gggttagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagt 600
 attggaatgg cacaggaaac cgaatcacat ggggtgccct cccttggttt tcaagtatct 660
 65 tggagtgtg cacaaaaatt aggtcatgcc ttcagtgtct tgttctttta acctaccctt 720
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaattg 780

gtgttcctcc taggttggaa gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
gtcagttgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaaatga 900
tgatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960
tcgcaaactc gcccttatcg taagaacaag ttccagaatt ttccctccac tatacgactc 1020
5 cagtattatg ttacaatcc attggatgag tgcagcatta taagaccttg gtgcccagaa 1080
aaatctgtcc tttttgttac caaacctgag gtcttttgga agataatgta gaaaaccact 1140
acctattgaa ggcctgtttt ggctaactcg tgcaaactct gatgatacct gcttatgtgg 1200
attcttttcc aactgctttt catttttaag tataaagact tagaaaacta gaataatgct 1260
tttacaata attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
10 atttaaacia gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
ccaaatcaaa aaccaacgc gtaaaacagg gcagtatttg tgttcctaata tttaaaaagc 1440
tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
acatacagca ttgtacatta caatgaaaat gtgtaactta agggatttat atatataaat 1560
acatatatac ctttgtaacc tttatactgt aaataaaaaa gttgcttttag tcaaaaaaaa 1620
15
<210> 33
<211> 2968
<212> DNA
<213> Human
20
<400> 33
gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
25 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180
gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
gatgatgatc ggactaaaga agaaagggct tatgacaaag caaacggag gattgagaaa 300
cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
gtacttgggc atgtggacac aggggaagaca aaaattctag ataagctccg tcacacacat 420
30 gtacaagatg gtgaagcagg tggatcaca caacaaattg gggccaccaa tgttcctctt 480
gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
35 aataagattg ataggttata tgattggaaa aagagtcctg actctgatgt ggctgctact 780
ttaaagaagc agaaaaagaa taaaaaagat gaatttgagg agcgagcaaa ggctattatt 840
gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
acttttgtgt ctttgggtacc tacctctgca catactgggt atggcatggg aagtctgatc 960
taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgaca ctgtgaagag 1020
40 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
atcttgatca atgggcgttt gaaggaagga gatacaatca ttgttcctgg agtagaaggg 1140
cccattgtaa ctcagattcg aggcctcctg ttacctctc ctatgaagga attacgagt 1200
aagaaccagt atgaaaagca taaagaagta gaagcagctc agggggtaaa gattcttggg 1260
aaagacctgg agaaaacatt ggctggttta cccctccttg tggcttataa agaagatgaa 1320
45 atccctgttc ttaaagatga attgatccat gagttaaagc agacactaaa tgctatcaaa 1380
ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttctttgga agctctactg 1440
gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500
aaagatgta tgaaggcttc agtgatgttg gaacatgacc ctcagtatgc agtaattttg 1560
gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatagttt aggagttaga 1620
50 attttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgaa 1800
gcaggtcagg tgaaacaggg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
55 gaagtttgtg taaaaataga acctatccct ggtgagtcac ccaaaatgtt tggaagacat 1980
tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040
gactgggtca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100
gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160
gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
60 gacttaagta tggaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
aacttacact ggtttgacag tggtcagtta catgtcccca cagttccaat gtgcctgttc 2340
actcacctct cccttcccca acccttctct acttggtgc tgttttaag tttgcccttc 2400
cccaaatttg gatttttatt acagatctaa agctctttcg attttatact gattaaatca 2460
gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
65 acgtaagaaa tacttcttta tttatgcata ttcttcccac agtgattttt ccagcattct 2580
tctgccatat gccttttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
tgatcgggtt agtagagatt ttatacat

<210> 34

<211> 6011

10 <212> DNA

<213> Human

<400> 34

15

20 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgcac tcggagcggg 60
accgccccgg actccccctc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
cggtctgagc cgagcgcagc acccccgcg ccccgcgcca gaagtttggg tgaaccgggc 180
tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240
ggaactcccc cggcccaagg ctctgtgggt cggggtcgcg cggccgcaga aggggcgggg 300
tccgcccgcg aggggaggcg cccccggga cccgagaggg gggtagggac cgcgggctgc 360
tggtgcggcg gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccgccccg 420
gctgcgagga ggaggcgcg gcggcgcagg aggatgtact tggtagcggg ggacaggggg 480
ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540
tccggcaccc gggcgctggt ctgctgccc tgtgacgagt ccaagtgcga ggagcccagg 600
aaccgccccg ggagcatcgt gcaggcgctc tgcggctgct gctacacgtg gccagccag 660
gggaacgaga gctgcggcg cacttccggg atttacggaa cctgcgaccg ggggctgcgt 720
30 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780
gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840
attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960
gagaagccag attgctccaa ggcccgtgt gaagtccagt tctctccacg ttgtcctgaa 1020
35 gattctgttc tgatcgaggg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080
tgctgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320
40 agatgcgagt gtctctctgg cttatgtggg ttccccgtgt gtgaggtggg atccactccc 1380
cgcatagtct ctctgtggcg tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440
aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
45 cagtgtggtg agataaactg cgagaggtag tacgtgcccg aaggagagtg ctgcccagtg 1620
tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgccaa tggcctgatc 1680
cttgcaccag gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggg 1740
gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
ggggagtgtt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
ggggagtatt caaactgcac tctgacacgg aaggactgca ttaatgggtt caaacgcgat 1920
50 cacaatggtt gtccgacctg tcagtgcata aacaccagc aactatgttc agaacgtaaa 1980
caaggctgca ccttgaactg tcccttcggg ttccttactg atgccccaaa ctgtgagatc 2040
tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
cttggaattg tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
55 tgcaagtgca gagaggcctc tgettccagt gggccacca tcctgtcggg cacttgtctc 2280
accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgctgtggc 2400
aaccaccaca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460
aagccagagc tcagtactcc ctccatttgc cacgcccctg gaggagaata ctttgtggaa 2520
60 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
tgtgagacag aggtgtgccc accgctgtc tgccagaacc cctcacgcac ccaggattcc 2640
tgctgcccac agtgtacaga tcaacctttt cggccttcc tgtcccga taacagcgta 2700
cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
gacgtttgta ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgagtcctgc 2820
65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtgcc ctactgcata 2880
aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000
 tgcaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagttgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 aaccatcgag gagaggttga cctggagggtt cccctgtggc ccacgcctag tgaaaatgat 3180
 5 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgctctcteta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgctggt atcgaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccagggtg gacagttccc agagaatgct aagaattgca 3480
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaact agaatttgtg cacttgctta gtggattgta 3660
 ttggattgtg acttgatgta cagcgctaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cacttttctt caagataact gaccaagtgt tttcttagaa 3780
 15 ccaaagtttt taaagttgct aagatatatt tgcctgtaag atagctgtag agatatattg 3840
 ggtggggaca gtgagtttgg atggggaaag ggggtggagg gtggtggtgg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggg aacataaaaag cagttcagtg gccagagggt 3960
 tatttttttc ctattgctct gaagactgca ctgggtgctg caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccttagaa ctaccagacg 4080
 20 agcacatcag aaccttttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgtagcgg catttctcta 4200
 aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
 25 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440
 ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
 gactgttttg ggattctttt tccttattat atactgattc tacaaaatag aaactacttc 4560
 attttaattg tatattatc aagcaccttt gttgaagctc aaaaaaatg atgcctcttt 4620
 aaacttttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680
 30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttcctg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
 gtgtgtgctg gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
 35 attcctttat taaaatcttc ctcatcttga tttgctttca gttggttttc aatttgctca 5040
 ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100
 tttttttttt tcaaacaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
 aagtttggtg tagtatgcct caaatataac tgactgtata ctatagtgg aacttttcaa 5220
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280
 40 tgcttggtgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340
 ttttgtaaag gaactttcaa gtattgttgt aaatacttgg acagagggtg ctgaacttta 5400
 aaaaaaatta atttattatt ataattgacct aatttattaa tctgaagatt aaccattttt 5460
 ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgttct agctgtttgc atcaaaggaa 5520
 45 aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580
 tacattacaa aatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
 caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttactttggt 5820
 tcctgttgtg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880
 50 cacttgaggt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65 mylvagdrql agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60
 gccytcasgg nescggtfgi ygtcdrqlrc virpplngds lteyeagvce denwtdqll 120
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieec kpdcskarce 180
 vqfsprcped svliegyapp geccpplsrc vcnpagclrk vcqpgnlnil vskasgkpge 240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgdmdfr mdncrfrcrq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 ctfcqcvnge rhcvatvcgq tctnpvkvpq eccpvceep iitvdppacg elsnctltrk 480
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdagnceic ecrprpkkr 540
 piicdkycpl gllknkhgcl icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
 ppilsgtclt vdghhkhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsq cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfssescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwdldsthe 840
 yclqggqtlcs tvscppplpcv epinvegsc pmcpemyvpe ptnipiekt nhrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiiaflfi 960
 nqkkqwipll cwyrtpstkps slnnqlvsd ckkgttrvqv ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

25 gcagtacctg gagtgcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggcgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
 ccagaactcg gtcctatattt acagattgag aaactatggt tcaagaagag aggacggggc 300
 30 ttgagggaaat ctctgatctc tctttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggtctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcagggggat gatctgggtc 480
 ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctggttagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgatttc caacttttaa acattgcatg tcttttgcca ttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
 gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaatgtta aaaccctaata 300
 50 tgcagttcct tttttaaat attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtaactt taccaccgaa ttgttcactt gactttaaga 60
 aaccataaa gctgcctggc tttcagcaac aggcctatca acaccatggt gacttccat 120
 aaggacacc gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
ggaatattgg tgggcccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
ttcgcaccgg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
tcaaaggctt ctttggaaaa actggaaaga aagcagttta agcagtttct gtgggtctaa 600
15 gcagatggac tcagagggtg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

ctttttgttt gggttttcca atgtagatgt ctacagtgaat tgtgcagata tactttgttc 60
25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
gcctcccac taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30 tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
ttttttgttt ttacacgaa tggaaaaatg atgtgttaagt ggtatagatt ttaatcagct 480
aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600
atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgagtt 60
ctgggttagtt tttgtaggct cattatggtt agggctcgta agatgtatat aagaacctac 120
45 ctatcatgct gtatgtatca ctcatccat ttcatgttc catgcatact cgggcatcat 180
gctaataatgt atccttttaa gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
acttccttca cagtgccgtg tctaccacta caaggactgt gcacttaagt aataattttt 420
50 taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
tgaagagatc agtagtaaga attccatttt cctcatcag tgaagacacc acaaattgaa 660
actcagaact atatttctaa gcctgcattt tcaactgatgc ataattttct tagtaattatt 720
55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
ttaattttat gagaagggtat tcttcatttt aattgctttt gggattactc cacatctttg 840
tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900
attggattga catatgggtt gccagcctat ggggtttacag gcattgcccc aacatttctt 960
tgagatctat atttataagc agccatggaa ttctattat gggatgttgg caatcttaca 1020
60 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tggttactct 1140
ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
tggaataaag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
65 tgaaaaaa

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
taacccccgg ctatcagtcg ggatggttgc caccctcct gctgtaggat ggaagcagcc 180
atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcatg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
15 ggaggaggga ggagctggta gggagatgct ggctttacct aaggctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttggg atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa tttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaatact gtaagctaag cagggtcagg 840
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgag ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagtagcg atttgggtgtg aaaaaaa

25

<210> 42
<211> 956
<212> DNA
<213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60
ggaaggagcc cctgagtcg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcgggca gggacccaaa gcaggatgac 300
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgcctctg acagatggac 420
40 gcaggccctg tccagccccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccaggg gggcgagaaa aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcggttgc gcagcgggtg 600
gaaggaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaatt cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggcgg ggactgctgg ctacgcctcc gctgtgtcct ccctcccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtggt 900
ggatttctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
<211> 536
<212> DNA
<213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt ctaaagtgtt aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtctttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa ggggttagtt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
attttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaataatta tggtagctaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggtt accagt

<210> 44
<211> 1630
<212> DNA
<213> Human

5

<400> 44

10 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctctg gagggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttaggcccag gacttggggc tccagctcat ctgttccttc tgggcccatt 360
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggg tgcttatttg gaaagagaga gacaaagagt 480
tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtggtgg gggctagtgg ggtttgaatt taggggccga 660
tgagcttggg tacgtgagca ggggtgttaag ttagggctct cctgtatttc tgggtcccct 720
20 ggaaatgtcc ccttcttcag tgtcagacct cagtcaccag gtccatctcg tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840
gcccagtgac ctggggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
tgtgattcag gtcccagggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt ctagagggtc agaattattg cttcaggatc agctgggggt 1020
25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagtg 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacaggggtg ctttggaatg 1200
aaagagtga cttagagggc tccttggggc tcaggaatgc tcctgctgct gtgaagatga 1260
gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30 ctgggtccct tgtagcacag gagactgggg ctaaggggcc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccaag ccagcgcttg gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
35 cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttcctg cattcatctg 1620
caaaaaaaaa

<210> 45
<211> 169
<212> DNA
<213> Human

40

<400> 45

45 tcttttgcct ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
taaaactggg ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga

<210> 46
<211> 769
<212> DNA
<213> Human

50

<400> 46

55 tgcaggctcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60
atttgtcgct ttactttttt ataaagtgtc acataaaatg tcatatttcc aaatttataa 120
acataactcc agttcttacc atgagaacag catgggtgatc acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aagggtgact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctec ttctctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65 ttgatataat tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA

<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
gtgaaaatta gtgactgggt aaggtgtgcc actgtacata tcatcatttt ctgactgggg 120
tcaggacctg gtcctagtcc acaaggggtg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
ggatgggtgg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15 gccttactta gctcctggca gaggggtgagt ggggacctac gaggttcaaa atcaaattggc 360
atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
tgggctcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
20 ccagaggccc ctgcaacttt gcggatttcc agaaggtgat aaaaagagca ctcttgagtg 660
ggtgccagc aatgttttaa atctatcagg cactactata agctgggtgt ttcttcctac 720
caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
tgaactctgg tgttgacagg taaaaggag aagagatggg gactgtgaag aggggagggc 840
ttccctcatc ttcctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
25 gcaatagatg gggcttccta ccatttgttg gttattgctg gggttagcca ggagcagtgt 960
ggatggcaaa gtaggagaga ggcccagagg aaagcccac tccctccagc tttgggtctt 1020
ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
aggtgaacag tctacactgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
ttatgaaact gaaaatcaaa tcaaggatatt gggaagaata atttcccctc gattccacag 1200
30 gagggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
caaggagtgt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440
gcagttgggc tgacctgaca aagccccag tttcctgttg caggttcttg gagaggatgc 1500
35 attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
aggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
gggggagtg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
tgaaaatttc cagaaatacc atttgggtgca tccctttgtt tctgtaatat taaactcagg 2100
45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaaag 2220
gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
tcgagttcca aagctctgat gaagaaaca gactccttga tgtgttactg atccactga 2340
ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
ggggtgtcc

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccaggc ccgttttcca tccctaagta ccattctctc atttggggcc ttctaggggt 240
65 ggggccctga gcttggtttg tagaagttg gtgctaatat aaccatagct ttaatcccca 300
tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt ttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttctcga 480
 gacggagtct cgtgtgttg cccaggctgg agtgcagtgg caccgtctcg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc ctcccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca caccgtggcc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggtgtctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtcctc 960
 acttcagtgg tgcacctgga tgggtgaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggatatta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctccta ccgctcggg agactggggc tcttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggcttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaagg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgaggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggc caggcaggga agggagctga agtgattcgg ggctaatacc 1380
 tcagatcgat gtatttctct ccctgggtct ccggagccct cttgtcaccg ctgctgccct 1440
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgtct 1500
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagttgga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccattgggaa cctggccaca 300
 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tgggggtggag 360
 35 ggagggtggg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatg ggcaagcatg 420
 tgogtgctg tgtgtgtgcg tgcccctccc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cactgtgagc tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag accttccct ggacctgggg gtctcgcctg atctcatgac 600
 cagggtgctaa atgacccgac atgcatcacc tgccttctga tgaccaacct ccctgtcccc 660
 40 gtcccgtgta cctgcccccg tggcgtctca cgggtgatgcc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgccctac aacccttcc ttgggtccga ggctggtagc tttgttccact 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc accctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgct attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

5 ctagcaagca ggtaaacgag ctttgtacaa acacacacag accaacacat ccgggggatgg 60
 ctgtgtgttg ctagagcaga ggctgattaa acactcagtg tgttggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gttaataaga aaatgtgcct tgctaactgt 180
 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgtgcc gctgccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctccccagc acaccctcat 300
 tacatgtgtc tgtctggcct gatctgtgca tctgctcggg gacgtccttg acaagtcggg 360
 aatttctcta tttctccact ggtgcaaaga gcggatttct ccctgcttct cttctgtcac 420
 ccccgtcct ctcccccagg aggtccttg atttatggta gctttggact tgcttccccg 480
 tctgactgtc cttgacttct agaattggaag aagctgagct ggtgaaggga agactccagg 540
 10 ccatcacaga taaaagaaaa atacaggaag aaatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gagggagaaa tggcttctag 660
 atggaatcag cagcggaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatcttg 780
 aaaaagctga actgcaaact tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 15 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgacct tccaaagtcc tacatacctt 960
 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgccat ggaaattaaa gttgaaaaag acttgaagac tggagaaagt acagtctctgt 1080
 cttccaatac ctctggccat cagatgactt taaaagggtac aggagtaaaa gtttaagatg 1140
 20 atgggcaaaa gtccagtgtg ttcagtaaag tgctaatacac aagttggagg t

<210> 52

<211> 1200

<212> DNA

25 <213> Human

<400> 52

30 aacagggact ctactctat caaccccagg ctggagtcgg gtgcgcccac cctgggtccc 60
 tgcaacctcc gcctcccagg ctcaagcaac tctcctgcct cagtcgctct agtagctggg 120
 actacaggca cacaccacca tgcccagcca atttttgcat tttttgtaga gacaggggtt 180
 cgccttctgt ccaggccggc atcatatact ttaaatacatg cccagatgac tttataacct 240
 aatacaatat atcaggttgg tttaaaaata attgcttttt tattattttt gcatttttgc 300
 accaacctta atgctatgta aatagttgtt atactgttgc ttaacaacag tatgacaatt 360
 35 ttggcttttt ctttgtatta ttttgtattt ttttttttta ttgtgtggtc tttttttttt 420
 ttctcagtggt tttcaattcc tccttggttg aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcat tgatgattgt cctattatat tagttataaa gtgtcattta 540
 atatgtagtg aaagttatgg tacagtggaa agagtagttg aaaacataaa catttggacc 600
 tttcaagaaa ggtagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggctc 660
 40 tgctactaat tagctataat ctttgcacaa attacatcac ctttgagtct cagttgcctc 720
 acctgtaaaa tgaaagaact ggatactctc taaggctcact tccagccctg tcattctata 780
 actctgttat gctgaggaag aaattcacat tgtgttaact gtatgagtca aactgaaaat 840
 gattattaaa gtgggaaaaa gccaatgtct tctcttagaa agctcaacta aatttgagaa 900
 gaataatctt ttcaattttt taagaattta aatattttta agggtttgac ctatttattt 960
 45 agagatgggg tctactctg tcacccagac tggagtacag tggcacaatc atagctcact 1020
 gctgcctcaa attcatgggc tcaagtgate ctctgcctc tgcctccaga gtagctgcga 1080
 ctatgggcat gtgccaccac gcctggctaa catttgtatt gacctattta tttattgtga 1140
 tttatatctt tttttttttt tctttttttt ttttttacia aatcagaaat acttattttg 1200

50 <210> 53

<211> 989

<212> DNA

<213> Human

55 <400> 53

60 aagccaccac tcaaaacttc ctatacattt tcacagcaga gacaagtga cttttatttt 60
 tatgcctttt ttcctatgtg tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggctgactg tgcaggagtc caggagacct ctacaaatgc 180
 agagtgactc tttaccaaca taaaccctag atacatgcaa aaagcaggac ctttctcca 240
 ggaatgtgcc atttcagatg cacagcacc atgcagaaaa gctggaattt tccttggaa 300
 cgactgtgat agaggtgctt acatgaacat tgcactgtc tttctttttt tttgagacag 360
 gtttcgcttg tgcccaggct gagtgaatg cgtgatctca ctactgcaa ttccacctcc 420
 aggttcaagc atttctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggctaatt ttgtattttt gtagagatgg atttctccat ttggtcaggc ggtctcgaac 540
 cccaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
ttctctgaag tacttgataa aatttccaaa caaacacacat gtccacttca ctgataaaaa 720
atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
5 ttaatatatt tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtg c actggcgcaa 960
gcccggctca ccgcaatctc tgccacccg

<210> 54
10 <211> 250
<212> DNA
<213> Human

<400> 54
15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
aaagggcatt ctttaggaac tgcattctgg aaccacacc ttgatccaag agctagggaa 240
20 acttcagttg

<210> 55
<211> 2270
<212> DNA
25 <213> Human

<400> 55

30 gcgccccga gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60
ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacaccgcg ccgccacccc 120
gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180
ctcgccccgg gctaactctg cgcgccaaa tgagctcccg catcgccagg gcgctcgctt 240
tagtcgtcac ccttctccac ttgaccaggc tggcgtcttc cacctgcccc gctgcctgcc 300
actgcccct ggagggccc aagtgcgcgc cgggagtcgg gctgggtccg gacggctgcg 360
35 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaacgggg 540
aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
ttcctctgtg tccccagaa ctatctctcc ccaacttggg ctgtcccaac cctcggttg 660
40 tcaaagttac cgggcagtgc tgcgaggagt gggctctgta cgaggatagt atcaaggacc 720
ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780
agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtcc 840
ctgttttttg aatggagcct cgcactctat acaacccttt acaaggccag aaatgtattg 900
ttcaaacaac ttcattggtcc cagtgtcaca agacctgtgg aactggtatc tccacacgag 960
45 ttaccaatga caacctgag tgccgccttg tgaaagaac ccggatttgt gaggtgccc 1020
cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
aatccccga accagtgcag tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140
ccaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200
tgaagatgcg gttccgctgc gaagatggg agacattttc caagaacgct atgatgatcc 1260
50 agtcctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
cctagacaaa caaggagaa gagtgctaga atcagaatca tggagaaaat gggcggggg 1440
gggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
ggtattttcg aactgccaa ggtgctgggt cggatggaca ctaatgcagc cacgattgga 1560
55 gaatactttg cttcatagta ttggagcaca tggtactgct tcatttttga gcttgtggag 1620
ttgatgactt tctgttttct gtttgaatat tatttgctaa gcatattttc tctaggcttt 1680
tttctttttg ggttctaca gtcgtaaaag agataataag attagttgga cagtttaaa 1740
cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccctcccttc ctgaaggggg 1800
acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
60 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920
tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980
tatggaatta accatttaat aaagaaatat ttacctata tctgagtgtg tgccattcgg 2040
tattttttaga ggtgctccaa agtcattagg aacaacctag ctacagctact caattattca 2100
aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
65 ttataccttc agtagagaaa agtctttgca tataaagtaa tgtttaaaaa acatgtattg 2220
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

```

10  cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
    agcgctcgag ttggaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
    cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180
    tggtttgctt ggtctcaagg aactgcatc gtcaaactga tcccttgccc gttggaggag 240
    cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
    cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15  agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtggcc 420
    gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
    gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
    agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
    atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcgggcca cctgcagtgg 660
20  gtttactgct gttccatctc ccagactgc agcatgctgt gctctgcagc tggagagaag 720
    tcggtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
    agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
    gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
    acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25  tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
    tgggccttg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
    acattttttc cacatggtgg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
    tggacagctc ctagggtcct gtctcactg aagcacttat gccggaaagc ctttcgaagt 1200
    ttcctaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30  acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatoct 1320
    cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380
    tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
    tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
    aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35  aagatggtga agggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
    gaccctgtgc tgcgtt
  
```

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

```

45  ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
    gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
    tggaatgagc taaagcagcc gcctgggggtg ggaggccgag cccatttgta tgcagcaggg 180
    ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
    atgcccgagc agccctccct cactctccat cctgtccagc cctaattgtg caggtgggga 300
50  aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
    gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
    ccgagctega attcgtaatc atggtcatag ctgtttcctg
  
```

<210> 58
 55 <211> 1049
 <212> DNA
 <213> Human

<400> 58

```

60  atctgatcaa gaatacctgc cctggtcact ctgcggatgt ttctgtccac ttgttcacat 60
    tgaggaccaa gatatecttt tttacagagg cacttggtcg gtctaacaca gacacctcca 120
    tgacgacatg ctggtcaca ttttgcaagt ctgcagaagt cccctcccca gcctggacta 180
    cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65  gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
    ggatctacaa tttttagtag ttttccattg tgagtctggg tcatactttt actgcttgat 360
  
```


5 aaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggttttt cttgccactg ctttgtcaca 480
 ggacttttgct ggagagtttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttataatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctgggt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
 10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaatata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttggtcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggtccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 30 ccaattcaat gccacaccta ctggttaccc tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaaattta gtagtaatag cggccgc